Day 1 - Thursday 23rd May 2024
10th RWE, Market Access, Pricing & Reimbursement Global Congress 2024 Europe
Trends and Strategies to Optimise Value and Patient Access
Hilton London Kensington, London, UK
Robert Mitchell-Thain, CEO, PBC Foundation
MARKET ACCESS TRENDS & STRATEGIES
- Trends that will continue to impact, Market Access, Pricing and Reimbursement in healthcare
- Unlocking data from early access
- Effective communications with internal and external stakeholders
- Embracing the digital vision
- Future trends and developments in the healthcare distribution
Moderator:
Robert Mitchell-Thain, CEO, PBC Foundation
Panelist:
Esther Nzenza, Founder and CEO, Decisive Consulting Ltd.
Francis Pang, SVP, Global Market Access & Geographic Expansion, Orchard Therapeutics
Fabian Schmidt, Global Head, Market Access, HEOR & Policy, Recordati Rare Diseases
- Several changes will introduce elements of unpredictability and additional burdensome on innovative companies, especially small and mid-sized biotech.
- Several changes will introduce elements of unpredictability and additional burdensome on innovative companies, especially small and mid-sized biotech.
- The introduction of stricter requirements on environmental risk assessment (ERA) and medicine shortage will add layers of administrative burdens on companies.
- Overall, these changes (as well as other ongoing legislative proposals, such as the EU HTA and the EHDS) will have an impact on companies that decide to invest in the EU, with consequences that will also affect market access in Member States, patients, healthcare systems and EU competitiveness.
Matthias Heck, Sr Director, International TA Policy Strategy, Alexion Pharmaceuticals
Stefano Romanelli, Senior Government Affairs, EUCOPE
- When and how to integrate value planning into development
- Staying responsive to changing market conditions
- Trends to watch
- Enabling diverse perspectives through timely engagement
Esther Nzenza, Founder and CEO, Decisive Consulting Ltd.
- Trends in oncology launches in Europe over the past three years reveal a trend for immature data packages and significant challenges when it comes to clinical benefit assessments and pricing negotiations
- Analysis of recent HTAs highlight significant challenges in demonstrating overall survival benefit remain, given the highly complex and increasingly personalised nature of oncology treatment paradigms
- What strategies are manufacturers pursuing in order to overcome such challenges? Are pharma stakeholders opting for lower-risk / lower-return strategies?
Higia Vassoler, Associate Director – Pricing & Market Access, Red Nucleus
- Challenges and obstacles in bringing this highly complex therapies to market
- Stakeholder collaboration on the road towards a solution
- Lessons learned and applications for new entrants
- Strategies that can be taken to improve timely market access and access for patients
Ryotaro Ishikawa, Market Access Head Gene Therapies, Novartis Gene Therapies
- This talk will shed light on how internal decisions on price types and managed entry agreements can drive the profitability of the business, and how to avoid blind spots for profitability.
- How external factors influence the choice of Price Governance will be discussed
- Examples of the actual decision-making process and the underlying key rationale towards Recordati Rare Diseases’ Price Governance model.
Fabian Schmidt, Global Head, Market Access, HEOR & Policy, Recordati Rare Diseases
- What does working with PAGs mean?
- How do we optimise that work so everybody wins?
- How do we optimise collaboration in an open, ethical way.
Robert Mitchell-Thain, CEO, PBC Foundation
- How use of data has expanding
- How we access that data is changing
- Case studies of use at NICE
Shaun Rowark, Associate Director for Data Access and Analysis, NICE
- As the leader of a rare disease patient organisation Kirsty will share perspectives on how to do patient group engagement right…and how to avoid getting it terribly wrong.
Kirsty Hoyle, CEO, Metabolic Support UK
- The use of RWD early in the process to boost trial diversity and inclusion
- Challenge in setting diversity goals early in clinical trial planning
- Development of a diversity plan to ensure adequate representation of racial and ethnic subgroups in clinical trials
- Utilizing RWE in the post-marketing setting to complement clinical trial findings and support post marketing requirements or commitments for safety and efficacy data in a diverse patient population
Riad Dirani, VP of Global HEOR, Medical Operations & Excellence, Teva
- Why is RWE increasingly being recognised and acknowledged as an evolution in product research and development.
- How does RWE help regulators, pharmaceutical companies and clinicians better identify trends and patterns in patient outcomes
- How can you make sure that only quality, reliable and relevant information are collected?
- How is it use to reduce risk and increase safety?
- Its use in supporting a robust post market surveillance and accelerating products to market
Moderator:
Matthias Heck, Sr Director, International TA Policy Strategy, Alexion Pharmaceuticals
Panellists: Robert Mitchell-Thain, CEO, PBC Foundation
Dr Samir Khan, Founder and Managing Director, Lighthouse Innovations Ltd
Robert Mitchell-Thain, CEO, PBC Foundation
